Tumors Evolve Hidden Escape Routes That Dodge Immune Attack in Lung Cancer
New research reveals how lung cancer subclones develop distinct immune evasion strategies, complicating immunotherapy response.
Latest breakthroughs in cancer research, treatment, and prevention
484 articles
New research reveals how lung cancer subclones develop distinct immune evasion strategies, complicating immunotherapy response.
Memorial Sloan Kettering-led trials produced 11 new FDA-approved cancer therapies in a single year, spanning multiple tumor types.
New research reveals how corticotroph pituitary tumors develop resistance to temozolomide through clonal selection of high MGMT-expressing cells.
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
Adding targeted radiation to standard therapy reduced progression by 46% across multiple cancer types in the EXTEND trial.
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
MYC protein doesn't just fuel tumor growth — it also repairs DNA damage from chemotherapy, revealing a key resistance mechanism.
NCI-sponsored trial evaluates safety and optimal dosing of immune checkpoint blockade following standard chemoradiation in locally advanced cervical cancer.
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Scientists identify CD300ld as a key mechanism by which tumor-infiltrating neutrophils silence CD8+ T cells, opening a new immunotherapy target.